Compile Data Set for Download or QSAR
Report error Found 50 Enz. Inhib. hit(s) with all data for entry = 50012626
TargetNuclear receptor subfamily 1 group I member 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558874(CHEMBL4794578)
Affinity DataEC50: <5.01E+4nMAssay Description:Inhibition of human PXRMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558869(CHEMBL4747186)
Affinity DataIC50: 0.158nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558860(CHEMBL4780638)
Affinity DataIC50: 3.20nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558861(CHEMBL4746922)
Affinity DataIC50: 6.30nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558863(CHEMBL4751816)
Affinity DataIC50: 6.30nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558859(CHEMBL4752817)
Affinity DataIC50: 7.90nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558879(CHEMBL4749895)
Affinity DataIC50: 7.90nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558866(CHEMBL4780229)
Affinity DataIC50: 7.90nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558871(CHEMBL4753216)
Affinity DataIC50: 10nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558872(CHEMBL4786263)
Affinity DataIC50: 10nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558873(CHEMBL4784139)
Affinity DataIC50: 10nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558858(CHEMBL4761952)
Affinity DataIC50: 13nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558878(CHEMBL4756758)
Affinity DataIC50: 13nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558877(CHEMBL4784513)
Affinity DataIC50: 13nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558876(CHEMBL4784679)
Affinity DataIC50: 13nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558874(CHEMBL4794578)
Affinity DataIC50: 13nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558870(CHEMBL4743843)
Affinity DataIC50: 13nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558867(CHEMBL4741733)
Affinity DataIC50: 13nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558875(CHEMBL4756244)
Affinity DataIC50: 16nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558865(CHEMBL4740170)
Affinity DataIC50: 16nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558874(CHEMBL4794578)
Affinity DataIC50: 16nMAssay Description:Inhibition of LRRK2 G2019S mutant in human ANK cells assessed as reduction in Ser935 phosphorylationMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558874(CHEMBL4794578)
Affinity DataIC50: 32nMAssay Description:Inhibition of LRRK2 in human AHE cells assessed as reduction in Ser935 phosphorylationMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558858(CHEMBL4761952)
Affinity DataIC50: 50nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558879(CHEMBL4749895)
Affinity DataIC50: 63nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558861(CHEMBL4746922)
Affinity DataIC50: 63nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558862(CHEMBL4795075)
Affinity DataIC50: 63nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558864(CHEMBL4760344)
Affinity DataIC50: 63nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558860(CHEMBL4780638)
Affinity DataIC50: 79nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558865(CHEMBL4740170)
Affinity DataIC50: 79nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558878(CHEMBL4756758)
Affinity DataIC50: 79nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558866(CHEMBL4780229)
Affinity DataIC50: 100nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558867(CHEMBL4741733)
Affinity DataIC50: 126nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558873(CHEMBL4784139)
Affinity DataIC50: 126nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558862(CHEMBL4795075)
Affinity DataIC50: 158nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558859(CHEMBL4752817)
Affinity DataIC50: 158nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558877(CHEMBL4784513)
Affinity DataIC50: 158nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558875(CHEMBL4756244)
Affinity DataIC50: 158nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558874(CHEMBL4794578)
Affinity DataIC50: 158nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558869(CHEMBL4747186)
Affinity DataIC50: 158nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558872(CHEMBL4786263)
Affinity DataIC50: 200nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558868(CHEMBL4759051)
Affinity DataIC50: 200nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558864(CHEMBL4760344)
Affinity DataIC50: 200nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558876(CHEMBL4784679)
Affinity DataIC50: 251nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558863(CHEMBL4751816)
Affinity DataIC50: 316nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558871(CHEMBL4753216)
Affinity DataIC50: 398nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558870(CHEMBL4743843)
Affinity DataIC50: 631nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558868(CHEMBL4759051)
Affinity DataIC50: 3.16E+3nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetSolute carrier organic anion transporter family member 1B1(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558874(CHEMBL4794578)
Affinity DataIC50: 1.26E+4nMAssay Description:Inhibition of human OATP1B1More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558874(CHEMBL4794578)
Affinity DataIC50: 6.31E+4nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetCytochrome P450 3A4(Human)
Gsk Pharmaceuticals R&D

Curated by ChEMBL
LigandPNGBDBM50558874(CHEMBL4794578)
Affinity DataIC50: 1.58E+5nMAssay Description:Inhibition of human CYP3A4More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed